Service Hotline +86 400-068-7188

Chinese Medicine Injection Industry Prospects and Investment Forecast Report, 2013-2017

Chinese Medicine Injection Industry Prospects and Investment Forecast Report, 2013-2017

Chinese Medicine Injection Industry Prospects and Investment Forecast Report, 2013-2017

A must-have for enterprise medium to long-term strategic planning

Without deep industry knowledge, it will be difficult to gain any return

English Version:USD7900

Including: Paper back + Electronic Copy + Invoice

Customer Hotline:+86 755 - 82925195 / 82925295

Free Hotline:+86 400-068-7188After-sales Hotline: +86 755-33013088

The Ministry of Commerce of the People's Republic of China designated Qianzhan Industrial Research Institute as the only "regional workstation for dealing with trade friction" in the Guangdong-Hong Kong-Macao Greater Bay Area

Special Statement

We are aware of that the content of our products have been stolen by some ones who changed the design and used it to deceive customers as it is their own products. Customers who are misled may experience no product received or an incomplete product. Therefore, Qianzhan Industrial Research Institute encourage you to arrange an in-person visit to our company before you make the purchase. Qianzhan has the sole copyright of all research reports. We have never had partnership or affiliated with any third party agent. Please recognize the"前瞻"trademark when purchasing reports.To have better investment return or strategic outcomes, you must have a forward-looking vision. Qianzhan Industrial Research Institute - China's leading industry consulting institutions provide you with all the things you need in business!

* The table of contents and the rest of this report are originally created by Qianzhan. Without any prior written permission, it is prohibited to copy or reproduce in any way. To have better investment return or strategic outcomes, you must have a forward-looking vision!

  • Table of Contents

  • Content Summary

Chinese Medicine Injection Industry Prospects and Investment Forecast Report, 2013-2017

Reporting core values

Major characteristics of this report are forward-looking and timeliness. Base on the forward-looking analysis of massive research data, we further analyze the development scale and competitive landscape of Chinese medicine injection industry. Along with the industry development route and our practical experience, we analyze and predict the future development prospect of Chinese medicine injection industry. This report contains a high value for both industry manufacturers and investment corporations that they can accurately know the latest industry development trend, obtain market opportunities and determine an insightful operation strategy and development direction. In the meantime, it is the first heavy weight report to analyze the up/down-stream industry chain and industry leading corporations of Chinese medicine injection industry in an overall and systemic way.

Main Contents of report

Chinese medicine injection is a product of Chinese medicine modernization. Basing on the accurate healing effect of traditional Chinese medicine, it changes the traditional drug delivery and fastens the healing effect as well as widens the serviceable range of Chinese medicine. The Chinese medicine injection has been widely used in clinical cases especially in the fields of cardiovascular and cerebrovascular diseases treatment and serious respiratory system diseases. It is with an irreplaceable advantage which the chemicals do not possess.

Comparing with traditional Chinese medicine, Chinese medicine injection is an innovation new medicine. The whole industry is on the babyhood but it develops fast that it takes the biggest market share in the field of Chinese medicine. The annual growth rate of Chinese medicine injection market is over 30% from 1999 to 2006. There is a stop and industry reorganization in 2006 due to the Chinese medicine injection “houttuynia cordata event”. Since then the industry develops in a stable and low-speed way. Currently, market scale of Chinese medicine injection has exceeded 30 billion Yuan.

There are 141 Chinese medicine injections by May 21st, 2011 (statistic according to approval product names, for changing formulations varieties it is calculated by different categories). In current years, the growth rate of various Chinese medicine injections has exceeded the average level of Chinese medicine industry (the average level is about 20%). And there are many products with a compound growth rate of over 30%.

According to data from the Southern Medicine Economic Institute, among the ready-made medicine in 9 major cities in 2010, injection medicament form takes a biggest proportion of about 35% and exceeds traditional medicament forms such as capsule and troche. The Chinese medicine injection is widely used in 5 major diseases and gains a good healing effect. The 5 major diseases are cardiovascular and cerebrovascular diseases, respiratory system diseases, neoplastic diseases, musculoskeletal system diseases and digestive diseases. The cardiovascular and cerebrovascular diseases take the biggest proportion which is about 59%.

Due to the frequent safety issues, SFDA stopped the examination of Chinese medicine injection since 2008, and started the evaluation of the products which ware selling in the market since 2009. Until the Tasly injection Danshen Phenolic Acids got a new drug certificate which is approved by the State Food and Drug Administration in April, 2011, that the situation began to change a bit. This event means that the examination and approval of Chinese medicine injection is available again. The loosening policies will bring fast development and new opportunities for the industry.

In spite of the policies advantages, corporations gradually pick up confidence of Chinese medicine injection. Kunmin Pharmaceutical CO., Ltd. proposed an additional issue scheme on October 15th, 2011 that would issue no more than 68 million stocks which may raises funds of 700 million Yuan, and would invest 4 projects which may cost 928 million Yuan. The raising fund will be used to improve the production capacity of internationalization pharmaceutics, small volume injection production line and subsidiary company, the Kunmin Chinese Medicine Factory, as well as technical center innovation capability construction. The additional project of Kunmin Pharmaceutical CO., Ltd. is promising.

Major characteristics of this report are forward-looking and timeliness. Base on the forward-looking analysis of massive research data, we further analyze the development scale and competitive landscape of Chinese medicine injection industry. Along with the industry development route and our practical experience, we analyze and predict the future development prospect of Chinese medicine injection industry. This report contains a high value for both industry manufacturers and investment corporations that they can accurately know the latest industry development trend, obtain market opportunities and determine an insightful operation strategy and development direction. In the meantime, it is the first heavy weight report to analyze the up/down-stream industry chain and industry leading corporations of Chinese medicine injection industry in an overall and systemic way.

Here, we’d like to express our sincere gratitude to Southern Medicine Economic Institute, National Statistics Bureau of China, International Information Institute, National Institute of the Ministry of Commerce, National Tsing Hua University Library, Institute of Market Economy of the State Council Development Research Center, and Beijing Qinghua Forward Market Research Center, etc. Thank you so much!

 

Qianzhan Business Information Co., Ltd. Industry Research College
Research Team of Chinese Medicine Injection

For any special needs, please contact us.Customize Your Report

  • The National Bureau of Statistics Foreign-related investigation Permission

  • National Innovation Company and Dual Software Certified Enterprise

  • The only DRC desginated Enterprise of the Industry Yearbook

  • National Ministry of Commerce designated Industrial Early Warning and Monitoring Workstation

  • Guangdong Province Enterprise of Observing Contract and Valuing Credit

Qianzhan Industrial Research Institute· The leading company of China Business Consulting

  • 01

    Qianzhan is an industry consulting service provider with national innovation company qualification, independent research and development of industrial big data and Dual Software Certification.

  • 02

    Qianzhan is a consulting and research organization that has been engaged in business consulting for over 16 years in China.

  • 03

    Qianzhan is a consulting service provider with a team of nearly 300 industrial researchers and analysts.

  • 04

    Qianzhan is a consulting service provider with an in-house expert pool of 1200 experts.

  • 05

    Qianzhan is a research and consulting organization that have served 180000 clients and received over positive comments from 100000 of our clients.

  • 06

    Qianzhan is an industry research and consulting organization that has been designated by the highest authority, the DRC, to prepare the yearbook.

  • 07

    Qianzhan is an industry planning and consulting organization that adopts the internationally synchronized SCP scientific analysis model and the perfect industry chain research map to guide the business planning and consulting.

  • 08

    Qizhan is a consulting service organization that helps enterprises to solve the five aspects of industry research, planning, strategic design, capital operation and implementation.

What Else do We Offer

Contact Us

Shenzhen Headquarter

Free Hotline:+86 400-068-7188

Customer Hotline:+86 755 - 82925195 / 82925295

Email Address:service@qianzhan.com

3rd Floor, FIYTA Building West, High Tech South Avenue 1, Nanshan District, Shenzhen, China

Shanghai Office

Location:Rm.1106, Building 1, Jiayu International Plaza, Songhu Road, Yangpu District,
Shanghai, China